发育性癫痫性脑病的精准诊疗研究治疗进展
Research Progress on Precise Diagnosis and Treatment of Developmental and Epileptic Encephalopathies
DOI: 10.12677/acm.2025.151002, PDF,   
作者: 杨 涵, 蒋 莉*：重庆医科大学附属儿童医院神经内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童神经发育与认知障碍重庆市重点实验室，重庆
关键词: 发育性癫痫性脑病；遗传学病因；药物治疗；精准治疗；Developmental and Epileptic Encephalopathy (DEEs)； Genetic Etiology； Medication； Precise Treatment
摘要: 发育性癫痫性脑病(developmental and epilepsy encephalopathies, DEEs)是指起病于发育期，以精神运动发育迟缓或倒退为特征的一组癫痫性脑病综合征。DEEs病因及致病机制复杂，遗传因素占据主导地位。当前，病因驱动治疗已成为制定DEEs管理方案的核心，个别综合征亦有特定的药物适应症。本文综述了目前DEEs的遗传学病因及新型抗癫痫药物在DEEs中的应用前景。旨在优化治疗方案，强调个体化精准诊疗，为提高对这一罕见癫痫疾病的理解和管理提供理论支持。
Abstract: Developmental and epileptic encephalopathy (DEEs) refers to a group of epileptic encephalopathy syndromes that begin in the developmental period and are characterized by development delay or regression. The etiology and pathogenesis of DEEs are complex, with genetic factors dominating. Currently, etiology-driven treatment has become the core of DEEs management, and certain syndromes also have specific drug indications. This article reviews the current genetic etiology of DEEs and the prospects for applying novel antiepileptic drugs in DEEs. It aims to optimize treatment plans, emphasize individualized and precise diagnosis and treatment, and provide theoretical support for improving understanding and management of this rare epilepsy disease.
文章引用：杨涵, 蒋莉. 发育性癫痫性脑病的精准诊疗研究治疗进展[J]. 临床医学进展, 2025, 15(1): 6-12. https://doi.org/10.12677/acm.2025.151002

参考文献

[1] Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L., et al. (2017) ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 58, 512-521. [Google Scholar] [CrossRef] [PubMed]
[2] Zuberi, S.M., Wirrell, E., Yozawitz, E., Wilmshurst, J.M., Specchio, N., Riney, K., et al. (2022) ILAE Classification and Definition of Epilepsy Syndromes with Onset in Neonates and Infants: Position Statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 63, 1349-1397. [Google Scholar] [CrossRef] [PubMed]
[3] Symonds, J.D., Zuberi, S.M., Stewart, K., McLellan, A., O’Regan, M., MacLeod, S., et al. (2019) Incidence and Phenotypes of Childhood-Onset Genetic Epilepsies: A Prospective Population-Based National Cohort. Brain, 142, 2303-2318. [Google Scholar] [CrossRef] [PubMed]
[4] Bayat, A., Bayat, M., Rubboli, G. and Møller, R.S. (2021) Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy. Genes, 12, Article No. 1051. [Google Scholar] [CrossRef] [PubMed]
[5] Howell, K.B., Eggers, S., Dalziel, K., Riseley, J., Mandelstam, S., Myers, C.T., et al. (2018) A Population-Based Cost-Effectiveness Study of Early Genetic Testing in Severe Epilepsies of Infancy. Epilepsia, 59, 1177-1187. [Google Scholar] [CrossRef] [PubMed]
[6] Meisler, M.H., Hill, S.F. and Yu, W. (2021) Sodium Channelopathies in Neurodevelopmental Disorders. Nature Reviews Neuroscience, 22, 152-166. [Google Scholar] [CrossRef] [PubMed]
[7] Wirrell, E.C., Hood, V., Knupp, K.G., Meskis, M.A., Nabbout, R., Scheffer, I.E., et al. (2022) International Consensus on Diagnosis and Management of Dravet Syndrome. Epilepsia, 63, 1761-1777. [Google Scholar] [CrossRef] [PubMed]
[8] Sadleir, L.G., Mountier, E.I., Gill, D., Davis, S., Joshi, C., de Vile, C., et al. (2017) Not All SCN1A Epileptic Encephalopathies Are Dravet Syndrome. Neurology, 89, 1035-1042. [Google Scholar] [CrossRef] [PubMed]
[9] Maljevic, S. and Lerche, H. (2012) Potassium Channels: A Review of Broadening Therapeutic Possibilities for Neurological Diseases. Journal of Neurology, 260, 2201-2211. [Google Scholar] [CrossRef] [PubMed]
[10] Pippucci, T., Parmeggiani, A., Palombo, F., Maresca, A., Angius, A., Crisponi, L., et al. (2013) A Novel Null Homozygous Mutation Confirms CACNA2D2 as a Gene Mutated in Epileptic Encephalopathy. PLOS ONE, 8, e82154. [Google Scholar] [CrossRef] [PubMed]
[11] Absalom, N.L., Liao, V.W.Y., Johannesen, K.M.H., Gardella, E., Jacobs, J., Lesca, G., et al. (2022) Gain-of-Function and Loss-of-Function GABRB3 Variants Lead to Distinct Clinical Phenotypes in Patients with Developmental and Epileptic Encephalopathies. Nature Communications, 13, Article No. 1822. [Google Scholar] [CrossRef] [PubMed]
[12] Absalom, N.L., Liao, V.W.Y., Kothur, K., Indurthi, D.C., Bennetts, B., Troedson, C., et al. (2020) Gain-of-Function GABRB3 Variants Identified in Vigabatrin-Hypersensitive Epileptic Encephalopathies. Brain Communications, 2, fcaa162. [Google Scholar] [CrossRef] [PubMed]
[13] Qiao, Y., Li, L., Hu, S., Yang, Y., Ma, Z., Huang, L., et al. (2024) Ketogenic Diet-Produced Β-Hydroxybutyric Acid Accumulates Brain GABA and Increases GABA/Glutamate Ratio to Inhibit Epilepsy. Cell Discovery, 10, Article No. 17. [Google Scholar] [CrossRef] [PubMed]
[14] Nishi, T., Kondo, S., Miyamoto, M., Watanabe, S., Hasegawa, S., Kondo, S., et al. (2020) Soticlestat, a Novel Cholesterol 24-Hydroxylase Inhibitor Shows a Therapeutic Potential for Neural Hyperexcitation in Mice. Scientific Reports, 10, Article No. 17081. [Google Scholar] [CrossRef] [PubMed]
[15] Hedrich, U.B.S., Lauxmann, S., Wolff, M., Synofzik, M., Bast, T., Binelli, A., et al. (2021) 4-Aminopyridine Is a Promising Treatment Option for Patients with Gain-of-Function KCNA2-Encephalopathy. Science Translational Medicine, 13, eaaz4957. [Google Scholar] [CrossRef] [PubMed]
[16] Rodríguez-Muñoz, M., Cortés-Montero, E., Pozo-Rodrigálvarez, A., Sánchez-Blázquez, P. and Garzón-Niño, J. (2015) The ON: OFF Switch, Σ1r-Hint1 Protein, Controls GPCR-NMDA Receptor Cross-Regulation: Implications in Neurological Disorders. Oncotarget, 6, 35458-35477. [Google Scholar] [CrossRef] [PubMed]
[17] Nabbout, R., Mistry, A., Zuberi, S., Villeneuve, N., Gil-Nagel, A., Sanchez-Carpintero, R., et al. (2020) Fenfluramine for Treatment-Resistant Seizures in Patients with Dravet Syndrome Receiving Stiripentol-Inclusive Regimens. Journal of the American Medical Association Neurology, 77, Article No. 300. [Google Scholar] [CrossRef] [PubMed]
[18] Amin, S., Monaghan, M., Aledo-Serrano, A., Bahi-Buisson, N., Chin, R.F., Clarke, A.J., et al. (2022) International Consensus Recommendations for the Assessment and Management of Individuals with CDKL5 Deficiency Disorder. Frontiers in Neurology, 13, Article 874695. [Google Scholar] [CrossRef] [PubMed]
[19] Makridis, K.L., Friedo, A., Kellinghaus, C., Losch, F., Schmitz, B., Boßelmann, C., et al. (2022) Successful Treatment of Adult Dravet Syndrome Patients with Cenobamate. Epilepsia, 63, e164-e171. [Google Scholar] [CrossRef] [PubMed]
[20] Dalic, L., Mullen, S.A., Roulet Perez, E. and Scheffer, I. (2014) Lamotrigine Can Be Beneficial in Patients with Dravet Syndrome. Developmental Medicine & Child Neurology, 57, 200-202. [Google Scholar] [CrossRef] [PubMed]
[21] Falcicchio, G., Lattanzi, S., Negri, F., de Tommaso, M., La Neve, A. and Specchio, N. (2022) Treatment with Cenobamate in Adult Patients with Lennox-Gastaut Syndrome: A Case Series. Journal of Clinical Medicine, 12, Article No. 129. [Google Scholar] [CrossRef] [PubMed]
[22] O’Callaghan, F.J.K., Edwards, S.W., Alber, F.D., Hancock, E., Johnson, A.L., Kennedy, C.R., et al. (2017) Safety and Effectiveness of Hormonal Treatment versus Hormonal Treatment with Vigabatrin for Infantile Spasms (ICISS): A Randomized, Multi-Centre, Open-Label Trial. The Lancet Neurology, 16, 33-42. [Google Scholar] [CrossRef] [PubMed]
[23] Hancock, E.C., Osborne, J.P. and Edwards, S.W. (2013) Treatment of Infantile Spasms. Cochrane Database of Systematic Reviews, 2014, CD001700. [Google Scholar] [CrossRef] [PubMed]
[24] Westall, C.A., Wright, T., Cortese, F., Kumarappah, A., Snead, O.C. and Buncic, J.R. (2014) Vigabatrin Retinal Toxicity in Children with Infantile Spasms. Neurology, 83, 2262-2268. [Google Scholar] [CrossRef] [PubMed]
[25] González-Fernández, B., Sánchez, D.I., Crespo, I., San-Miguel, B., de Urbina, J.O., González-Gallego, J., et al. (2018) RETRACTED: Melatonin Attenuates Dysregulation of the Circadian Clock Pathway in Mice with CCL4-Induced Fibrosis and Human Hepatic Stellate Cells. Frontiers in Pharmacology, 9, Article No. 556. [Google Scholar] [CrossRef] [PubMed]
[26] Khan, S., Khurana, M., Vyas, P., et al. (2020) The Role of Melatonin and Its Analogues in Epilepsy. Reviews in the Neurosciences.
https://pubmed.ncbi.nlm.nih.gov/32950966/
[27] Bazil, C.W., Short, D., Crispin, D. and Zheng, W. (2000) Patients with Intractable Epilepsy Have Low Melatonin, Which Increases Following Seizures. Neurology, 55, 1746-1748. [Google Scholar] [CrossRef] [PubMed]
[28] Mercau, M.E., Calanni, J.S., Aranda, M.L., Caldareri, L.J., Rosenstein, R.E., Repetto, E.M., et al. (2019) Melatonin Prevents Early Pituitary Dysfunction Induced by Sucrose-Rich Diets. Journal of Pineal Research, 66, e12545. [Google Scholar] [CrossRef] [PubMed]
[29] Wan, L., Shi, X., Ge, W., Sun, Y., Zhang, S., Wang, J., et al. (2020) The Instigation of the Associations between Melatonin, Circadian Genes, and Epileptic Spasms in Infant Rats. Frontiers in Neurology, 11, Article 497225. [Google Scholar] [CrossRef] [PubMed]
[30] Sun, Y., Chen, J., Shi, X., Li, Z., Wan, L., Yan, H., et al. (2023) Safety and Efficacy of Melatonin Supplementation as an Add-On Treatment for Infantile Epileptic Spasms Syndrome: A Randomized, Placebo-Controlled, Double-Blind Trial. Journal of Pineal Research, 76, e12922. [Google Scholar] [CrossRef] [PubMed]
[31] Jain, S.V., Horn, P.S., Simakajornboon, N., Beebe, D.W., Holland, K., Byars, A.W., et al. (2015) Melatonin Improves Sleep in Children with Epilepsy: A Randomized, Double-Blind, Crossover Study. Sleep Medicine, 16, 637-644. [Google Scholar] [CrossRef] [PubMed]
[32] Coppola, G., Iervolino, G., Mastrosimone, M., La Torre, G., Ruiu, F. and Pascotto, A. (2004) Melatonin in Wake-Sleep Disorders in Children, Adolescents and Young Adults with Mental Retardation with or without Epilepsy: A Double-Blind, Cross-Over, Placebo-Controlled Trial. Brain and Development, 26, 373-376. [Google Scholar] [CrossRef] [PubMed]
[33] Vossler, D.G., Bainbridge, J.L., Boggs, J.G., Novotny, E.J., Loddenkemper, T., Faught, E., et al. (2020) Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Currents, 20, 245-264. [Google Scholar] [CrossRef] [PubMed]
[34] Niday, Z. and Tzingounis, A.V. (2018) Potassium Channel Gain of Function in Epilepsy: An Unresolved Paradox. The Neuroscientist, 24, 368-380. [Google Scholar] [CrossRef] [PubMed]

为你推荐